Payment overview · 2025
General Payments
$872.10
45 reported records · 15 companies
Healthcare provider profile · identity verified
James Christopher Sheppard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THOMSON, GA · NPI 1528075835
Verified facts
What the public records show
CMS Open Payments records show James Christopher Sheppard, MD received $872.10 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 513 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.36 | 20.9% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.22 | 17.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.66 | 10.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.87 | 8.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.52 | 6.7% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $47.22 | 5.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.12 | 5.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.93 | 4.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.86 | 4.6% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $32.67 | 3.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.14 | 3.7% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.85 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.52 | 2.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.22 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.94 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $872.10 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $149.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $128.28 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $91.66 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.87 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.12 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.99 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.09 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.09 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.52 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 291 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
291 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
291 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
513 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1401 | 300 |
| Amlodipine Besylate | Amlodipine Besylate | 1161 | 220 |
| Gabapentin | Gabapentin | 876 | 137 |
| Losartan Potassium | Losartan Potassium | 856 | 139 |
| Trazodone Hcl | Trazodone Hcl | 793 | 117 |
| Potassium Chloride | Potassium Chloride | 788 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 749 | 110 |
| Omeprazole | Omeprazole | 658 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 592 | 114 |
| Citalopram Hbr | Citalopram Hydrobromide | 571 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 563 | 124 |
| Donepezil Hcl | Donepezil Hcl | 538 | 45 |
| Eliquis | Apixaban | 513 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 506 | 25 |
| Tramadol Hcl | Tramadol Hcl | 504 | 107 |
| Mirtazapine | Mirtazapine | 489 | 41 |
| Sertraline Hcl | Sertraline Hcl | 487 | 52 |
| Lisinopril | Lisinopril | 471 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 456 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 449 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 438 | 83 |
| Furosemide | Furosemide | 437 | 73 |
| Carvedilol | Carvedilol | 421 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 412 | 127 |
| Famotidine | Famotidine | 387 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 378 | 52 |
| Buspirone Hcl | Buspirone Hcl | 371 | 46 |
| Metformin Hcl | Metformin Hcl | 371 | 81 |
| Celecoxib | Celecoxib | 367 | 81 |
| Memantine Hcl | Memantine Hcl | 347 | 23 |
| Spironolactone | Spironolactone | 347 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 338 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 308 | 129 |
| Levetiracetam | Levetiracetam | 293 | 17 |
| Jardiance | Empagliflozin | 291 | 57 |
| Ezetimibe | Ezetimibe | 272 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 23 |
| Meloxicam | Meloxicam | 251 | 78 |
| Simvastatin | Simvastatin | 249 | 50 |
| Allopurinol | Allopurinol | 244 | 49 |
| Montelukast Sodium | Montelukast Sodium | 242 | 70 |
| Alendronate Sodium | Alendronate Sodium | 239 | 64 |
| Prednisone | Prednisone | 233 | 125 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 215 | 48 |
| Paroxetine Hcl | Paroxetine Hcl | 181 | 16 |
| Bupropion Xl | Bupropion Hcl | 169 | 37 |
| Glimepiride | Glimepiride | 168 | 52 |
| Baclofen | Baclofen | 164 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 153 | 96 |
| Farxiga | Dapagliflozin Propanediol | 141 | 26 |
| Risperidone | Risperidone | 131 | suppressed |
| Finasteride | Finasteride | 128 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 128 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 126 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 32 |
| Ozempic | Semaglutide | 125 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 124 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 124 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 123 | 20 |
| Clonazepam | Clonazepam | 119 | 23 |
| Metformin Hcl Er | Metformin Hcl | 119 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 112 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 32 |
| Atenolol | Atenolol | 104 | 26 |
| Bumetanide | Bumetanide | 104 | 11 |
| Lamotrigine | Lamotrigine | 104 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 103 | 17 |
| Pregabalin | Pregabalin | 101 | 32 |
| Midodrine Hcl | Midodrine Hcl | 98 | suppressed |
| Alprazolam | Alprazolam | 97 | 14 |
| Fenofibrate | Fenofibrate | 96 | 13 |
| Trulicity | Dulaglutide | 94 | 17 |
| Aripiprazole | Aripiprazole | 91 | 17 |
| Lorazepam | Lorazepam | 91 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 91 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 87 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 62 |
| Divalproex Sodium | Divalproex Sodium | 71 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 38 |
| Divalproex Sodium Er | Divalproex Sodium | 68 | suppressed |
| Lovastatin | Lovastatin | 68 | 11 |
| Primidone | Primidone | 68 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 18 |
| Myrbetriq | Mirabegron | 67 | 18 |
| Meclizine Hcl | Meclizine Hcl | 64 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 18 |
| Sucralfate | Sucralfate | 61 | 11 |
| Ondansetron Odt | Ondansetron | 60 | 28 |
| Xarelto | Rivaroxaban | 60 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 28 |
| Mupirocin | Mupirocin | 58 | 39 |
| Mounjaro | Tirzepatide | 57 | 11 |
| Rybelsus | Semaglutide | 57 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Methocarbamol | Methocarbamol | 53 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | 17 |
| Latanoprost | Latanoprost | 50 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 21 |
| Nystatin | Nystatin | 49 | 31 |
| Fluconazole | Fluconazole | 48 | 31 |
| Warfarin Sodium | Warfarin Sodium | 48 | 13 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 47 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 44 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 17 |
| Insulin Aspart Flexpen | Insulin Aspart | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Olanzapine | Olanzapine | 44 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Cefdinir | Cefdinir | 41 | 33 |
| Nitroglycerin | Nitroglycerin | 41 | 21 |
| Ranolazine Er | Ranolazine | 40 | suppressed |
| Torsemide | Torsemide | 40 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 27 |
| Valsartan | Valsartan | 39 | 12 |
| Estradiol | Estradiol | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 38 | suppressed |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Colchicine | Colchicine | 37 | 14 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 35 | suppressed |
| Dutasteride | Dutasteride | 35 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 33 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Levofloxacin | Levofloxacin | 32 | 17 |
| Methimazole | Methimazole | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 22 |
| Promethazine Hcl | Promethazine Hcl | 29 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Multaq | Dronedarone Hcl | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 16 |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 11 |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 13 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $872.10 · 45 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, Briviact, CAPLYTA, COMIRNATY, CREON, JARDIANCE, Jornay PM, Kerendia, LINZESS, MOUNJARO, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error